330 related articles for article (PubMed ID: 16060128)
1. Long-term comparative results of C0 and C2 monitoring of CyA in renal transplanted patients.
Paydaş S; Balal M; Sertdemir Y; Seyrek N; Karayaylali I
Ren Fail; 2005; 27(4):409-13. PubMed ID: 16060128
[TBL] [Abstract][Full Text] [Related]
2. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[TBL] [Abstract][Full Text] [Related]
3. Correlation of C0 and C2 levels with lipid profiles in adolescent renal transplant recipients in the early and late posttransplant periods.
Soylu A; Kavukçu S; Türkmen MA; Kasap B; Soylu A; Bora S; Gülay H
Transplant Proc; 2006 Jun; 38(5):1286-9. PubMed ID: 16797283
[TBL] [Abstract][Full Text] [Related]
4. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
Kyllönen LE; Salmela KT
Transplantation; 2006 Apr; 81(7):1010-5. PubMed ID: 16612277
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine dose reduction in stable renal transplant patients with high C2 level: simplified method of single C2 measurement and individualization of C0 target.
Higgins RM; Kanji H; Hernon M; Harrison P; Lam FT; Kashi SH
Transpl Int; 2005 Jul; 18(7):806-10. PubMed ID: 15948859
[TBL] [Abstract][Full Text] [Related]
6. Effect of cyclosporine therapy with low doses of corticosteroids on idiopathic nephrotic syndrome.
Griveas I; Visvardis G; Papadopoulou D; Nakopolou L; Karanikas E; Gogos K; Stavianoudakis G
Artif Organs; 2010 Mar; 34(3):234-7. PubMed ID: 20447050
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
Delgado DH; Rao V; Hamel J; Miriuka S; Cusimano RJ; Ross HJ
J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
[TBL] [Abstract][Full Text] [Related]
8. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M
Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation.
Glanville AR; Morton JM; Aboyoun CL; Plit ML; Malouf MA
J Heart Lung Transplant; 2004 Oct; 23(10):1170-4. PubMed ID: 15477111
[TBL] [Abstract][Full Text] [Related]
10. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.
Ferraresso M; Citterio F; Ghio L; Romagnoli J; Edefonti A; Berardinelli L; Castagneto M
Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115
[TBL] [Abstract][Full Text] [Related]
11. A survey to determine the blood concentration of cyclosporine 2 hours postdose in stable renal transplant patients.
Jorga A; Holt DW; Yaqoob M; Whittaker C; Johnston A
Transplant Proc; 2004 Dec; 36(10):3239-41. PubMed ID: 15686737
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
[TBL] [Abstract][Full Text] [Related]
13. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
Domínguez J; Fuenzalida D; Norambuena R; Pais E; Cortes Monroy G; Llanos R
Transplant Proc; 2005 Apr; 37(3):1583-5. PubMed ID: 15866680
[TBL] [Abstract][Full Text] [Related]
14. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
Rodrigo E; Ruiz JC; Angeles de Cos M; Ruiz J; Gago M; Piñera C; Sánchez B; González-Cotorruelo J; Gómez-Alamillo C; Arias M
Transplant Proc; 2009; 41(6):2328-31. PubMed ID: 19715910
[TBL] [Abstract][Full Text] [Related]
15. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
Caforio AL; Tona F; Piaserico S; Gambino A; Feltrin G; Fortina AB; Angelini A; Alaibac M; Bontorin M; Calzolari D; Peserico A; Thiene G; Iliceto S; Gerosa G
Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients.
Kim SJ; Prasad GV; Huang M; Nash MM; Famure O; Park J; Thenganatt MA; Chowdhury N; Cole EH; Fenton SS; Cattran DC; Zaltzman JS; Cardella CJ
Transplantation; 2006 Oct; 82(7):924-30. PubMed ID: 17038908
[TBL] [Abstract][Full Text] [Related]
17. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation.
Morton JM; Aboyoun CL; Malouf MA; Plit ML; Glanville AR
J Heart Lung Transplant; 2004 Sep; 23(9):1035-9. PubMed ID: 15454168
[TBL] [Abstract][Full Text] [Related]
18. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
Takatsuki M; Chen CL; Chen YS; Wang CC; Lin CC; Yang CH; Yong CC; Liu YW
Clin Transplant; 2004 Dec; 18(6):694-9. PubMed ID: 15516246
[TBL] [Abstract][Full Text] [Related]
19. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients.
Mathias HC; Ozalp F; Will MB; Borland W; Payne C; Kerr M; Lockhart J; Murday AJ
J Heart Lung Transplant; 2005 Dec; 24(12):2137-43. PubMed ID: 16364862
[TBL] [Abstract][Full Text] [Related]
20. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]